Cardiff Oncology Inc (NASDAQ:CRDF) shares, rose in value on Friday, March 07, with the stock price down by -0.64% to the previous day’s close as strong demand from buyers drove the stock to $3.86.
Actively observing the price movement in the last trading, the stock closed the session at $3.88. Referring to stock’s 52-week performance, its high was $6.42, and the low was $2.01. On the whole, CRDF has fluctuated by -16.56% over the past month.
With the market capitalization of Cardiff Oncology Inc currently standing at about $256.45 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 87.5k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRDF’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of CRDF currently trading nearly -9.92% and -4.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.45, while the 7-day volatility ratio is showing 10.21% which for the 30-day chart, stands at 9.44%. Furthermore, Cardiff Oncology Inc (CRDF)’s beta value is 1.65, and its average true range (ATR) is 0.39.
A comparison of Cardiff Oncology Inc (CRDF) with its peers suggests the former has fared considerably weaker in the market. CRDF showed an intraday change of -0.64% in last session, and over the past year, it grew by 5.62%%.
Data on historical trading for Cardiff Oncology Inc (NASDAQ:CRDF) indicates that the trading volumes over the past 3 months, they’ve averaged 2.26 million. According to company’s latest data on outstanding shares, there are 66.52 million shares outstanding.
Nearly 10.13% of Cardiff Oncology Inc’s shares belong to company insiders and institutional investors own 34.48% of the company’s shares. The stock has fallen by -11.18% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDF stock heading into the next quarter.
